CNCE - コンサ―ト・ファ―マシュ―ティカルズ (Concert Pharmaceuticals Inc.) コンサ―ト・ファ―マシュ―ティカルズ

 CNCEのチャート


 CNCEの企業情報

symbol CNCE
会社名 Concert Pharmaceuticals Inc (コンサ―ト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コンサート・ファーマスーティカル(Concert Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は小分子医薬品の発見と開発に従事する。同社は医薬品の開発を通じて事業を行う。同社の重水素化化学物質プラットフォーム(DCEプラットフォーム)は各種治療領域にある可能性を有する。同社の製品好捕にはAVP-786、CTP-656、CTP-730、CTP-543、JZP-386等を含む。同社の製品候補であるCTP-656は、G551D突然変異を含むゲーティング変異を有する患者にある嚢胞性線維症の治療のために開発中次世代増強剤である。CTP-543はルキソリチニブを改変することでコンサートのジュウテリウム化学技術を応用することにより発見された。AVP-786はデキストロメトルファンと超低用量のキニジンの組み合わせである。CTP-730は各種炎症性疾患の治療の可能性を有するホスホジエステラーゼ4(PDE4)阻害剤である。   コンサ―ト・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。臨床段階の低分子薬の開発に従事。主要パイプライン製品候補は、多発性硬化症および脊髄損傷に関連した痙性のためのCTP-354、糖尿病性腎症のためのCTP-499、神経学的および精神障害のためのAVP-786など。   
本社所在地 99 Hayden Avenue Suite 500 Lexington MA 02421 USA
代表者氏名 Richard H. Aldrich リチャードH.アルドリッチ
代表者役職名 Independent Chairman of the Board Co-Founder
電話番号 +1 781-860-0045
設立年月日 38808
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 64人
url www.concertpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cnce
adr_tso
EBITDA EBITDA(百万ドル) 101.93900
終値(lastsale) 15.5
時価総額(marketcap) 362932887.5
時価総額 時価総額(百万ドル) 337.17640
売上高 売上高(百万ドル) 154.33700
企業価値(EV) 企業価値(EV)(百万ドル) 147.00540
当期純利益 当期純利益(百万ドル) 103.45900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Concert Pharmaceuticals Inc revenues increased from $35K to $10.5M. Net loss applicable to common stockholders decreased 32% to $17.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General_Admin exp decrease of 14% to $7.8M (expense) Investment Income increase from $292K to $1.3M (income).

 CNCEのテクニカル分析


 CNCEのニュース

   The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping  2021/03/24 12:59:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency Therapeutics, Inc. (NASDAQ: FREQ ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) Ibere Pharmaceuticals (NYSE: IBER-UN) Instil Bio, Inc. (NASDAQ: TIL ) (IPOed Friday) Odonate Therapeutics, Inc. (NASDAQ: ODT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Soleno Therapeutics, Inc. (NASDAQ: SLNO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus LabCorp to Review Structure And Capital Allocation Strategy Laboratory Corporation of America Holdings (NYSE: LH ) said its board is undertaking a review of its structure and capital allocation strategy to ensure the company is best positioned to unlock shareholder value while it continues to support patients and customers around the world.
   KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors  2021/03/19 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and bus
   Concert Pharmaceuticals to Present at Upcoming Investor Conferences  2021/03/02 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will present a corporate overview at the H.C. Wainwright and Oppenheimer virtual conferences in March.
   Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs - Stocks News Feed  2021/02/25 12:00:00 Stocks News Feed
CTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP‑543 Phase 3 Trial, to Initiate 1H2021 CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results Conference Call and Webcast Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #CNCE—Concert… Read More »Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
   Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021  2021/02/18 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The Company will host a conference call and webcast on February 25, 2021, to discuss 2020 financial results and provide a business update.
   KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors  2021/03/19 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and bus
   Concert Pharmaceuticals to Present at Upcoming Investor Conferences  2021/03/02 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will present a corporate overview at the H.C. Wainwright and Oppenheimer virtual conferences in March.
   Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs - Stocks News Feed  2021/02/25 12:00:00 Stocks News Feed
CTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP‑543 Phase 3 Trial, to Initiate 1H2021 CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results Conference Call and Webcast Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #CNCE—Concert… Read More »Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
   Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021  2021/02/18 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The Company will host a conference call and webcast on February 25, 2021, to discuss 2020 financial results and provide a business update.
   Concert crushed on PhII schizophrenia flop; Amgen's sotorasib gets BTD in China  2021/02/01 16:14:20 Endpoints News
Concert Pharmaceuticals stock tanked nearly 40% on Monday morning when a major Phase II flop left the biotech no choice but to ax its schizophrenia program. The move leaves Concert with just one Phase III candidate for alopecia areata in the pipeline, which CEO Roger Tung says is now the
   Concert Pharmaceuticals to Present at Upcoming Investor Conferences  2021/03/02 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will present a corporate overview at the H.C. Wainwright and Oppenheimer virtual conferences in March.
   Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs - Stocks News Feed  2021/02/25 12:00:00 Stocks News Feed
CTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP‑543 Phase 3 Trial, to Initiate 1H2021 CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results Conference Call and Webcast Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #CNCE—Concert… Read More »Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
   Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021  2021/02/18 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The Company will host a conference call and webcast on February 25, 2021, to discuss 2020 financial results and provide a business update.
   Concert crushed on PhII schizophrenia flop; Amgen's sotorasib gets BTD in China  2021/02/01 16:14:20 Endpoints News
Concert Pharmaceuticals stock tanked nearly 40% on Monday morning when a major Phase II flop left the biotech no choice but to ax its schizophrenia program. The move leaves Concert with just one Phase III candidate for alopecia areata in the pipeline, which CEO Roger Tung says is now the
   Mid-Day Market Update: Silver Surges 7%; Concert Pharmaceuticals Shares Plunge  2021/02/01 12:10:00 Benzinga
Midway through trading Monday, the Dow traded up 0.73% to 30,202.28 while the NASDAQ rose 2.16% to 13,352.59. The S&P also rose, gaining 1.4% to …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コンサ―ト・ファ―マシュ―ティカルズ CNCE Concert Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)